Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method

被引:6
作者
Fonseca de Jesus, Victor Hugo [1 ]
Costa Junior, Wilson Luiz [2 ]
Felismino, Tiago Cordeiro [1 ]
Calsavara, Vinicius Fernando [3 ]
Diniz, Alessandro Landskron [2 ]
de Castro Ribeiro, Heber Salvador [2 ]
de Godoy, Andre Luis [2 ]
de Farias, Igor Correia [2 ]
Fernandez Coimbra, Felipe Jose [2 ]
机构
[1] AC Camargo Canc Ctr, Med Oncol Dept, Rua Prof Antonio Prudente 211, Sao Paulo, SP, Brazil
[2] AC Camargo Canc Ctr, Abdominal Surg Dept, Sao Paulo, SP, Brazil
[3] AC Camargo Canc Ctr, Int Res Ctr CIPE, Dept Epidemiol & Stat, Sao Paulo, SP, Brazil
关键词
Survival; stage I; gastric; cancer; PERIOPERATIVE CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; SURGERY; RECURRENCE; ADENOCARCINOMA; MORTALITY; T2N0; EUS;
D O I
10.21037/jgo.2019.10.04
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Patients with stage I gastric cancer are considered to have an exquisite prognosis. Nonetheless, the fact that some patients experience disease relapse highlights that a subgroup might benefit from multimodality treatment. We aimed to evaluate the survival of patients with stage I gastric cancer and 1(x)k for harbingers of gastric cancer recurrence. Methods: We looked for patients with stage I gastric cancer treated exclusively with surgery from 1996 to 2015. The competing risks survival method was used to allow for concurrent causes of mortality. Also, we calculated subdistribution hazards (SH) to reveal factors associated with cancer recurrence and death from unrelated causes. Results: A total of 185 patients constitute the study population. 71hirty-seven patients had pT2N0 tumors. Most patients (80.5%) were treated with D2 lymphadenectomy. The probability of relapse at 5 years was 3.0% and 8.6% in the study population and the pT2N0 subgroup, respectively. Among all 26 deaths, only six were related to gastric cancer. In multivariate analysis, perineural invasion (PNI) was associated with increased risk of gastric cancer recurrence. Conclusions: The prognosis of stage I gastric cancer treated with D2 lymphadenectomy is excellent. PNI may indicate higher likelihood of recurrence. Further work in this field should account for the higher risk of death from unrelated causes.
引用
收藏
页码:1110 / +
页数:13
相关论文
共 24 条
[1]   Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Schmalenberg, Harald ;
Knopp, Hans-Georg ;
Georg .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2]  
[Anonymous], MANUAL STAGING CANC
[3]   Prognostic factors in stage IB gastric cancer [J].
Aoyama, Toru ;
Yoshikawa, Takaki ;
Fujikawa, Hirohito ;
Hayashi, Tsutomu ;
Ogata, Takashi ;
Cho, Haruhiko ;
Yamada, Takanobu ;
Hasegawa, Shinichi ;
Tsuchida, Kazuhito ;
Yukawa, Norio ;
Oshima, Takashi ;
Oba, Mari S. ;
Morita, Satoshi ;
Rino, Yasushi ;
Masuda, Munetaka .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (21) :6580-6585
[4]   Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Kim, Young-Woo ;
Yang, Han-Kwang ;
Chung, Hyun Cheol ;
Park, Young-Kyu ;
Lee, Kyung Hee ;
Lee, Keun-Wook ;
Kim, Yong Ho ;
Noh, Sang-Ik ;
Cho, Jae Yong ;
Mok, Young Jae ;
Kim, Yeul Hong ;
Ji, Jiafu ;
Yeh, Ta-Sen ;
Button, Peter ;
Sirzen, Florin ;
Noh, Sung Hoon .
LANCET, 2012, 379 (9813) :315-321
[5]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[6]   Defining a High-Risk Subgroup of Pathological T2N0 Gastric Cancer by Prognostic Risk Stratification for Adjuvant Therapy [J].
Du, Chunyan ;
Zhou, Ye ;
Huang, Kai ;
Zhao, Guangfa ;
Fu, Hong ;
Shi, Yingqiang .
JOURNAL OF GASTROINTESTINAL SURGERY, 2011, 15 (12) :2153-2158
[7]   Accuracy of EUS and CT imaging in preoperative gastric cancer staging [J].
Fairweather, Mark ;
Jajoo, Kunal ;
Sainani, Nisha ;
Bertagnolli, Monica M. ;
Wang, Jiping .
JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (08) :1016-1020
[8]  
Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706]
[9]   EARLY GASTRIC-CANCER - PROGNOSTIC FACTORS IN 223 PATIENTS [J].
FOLLI, S ;
DENTE, M ;
DELLAMORE, D ;
GAUDIO, M ;
NANNI, O ;
SARAGONI, L ;
VIO, A .
BRITISH JOURNAL OF SURGERY, 1995, 82 (07) :952-956
[10]   Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma? [J].
Gabriel, Emmanuel ;
Attwood, Kristopher ;
Narayanan, Sumana ;
Brady, Maureen ;
Nurkin, Steven ;
Hochwald, Steven ;
Kukar, Moshim .
JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (04) :659-670